Home
Ophthalmic Drugs
20 November - 21 November 2023
Ophthalmic Drugs

Conference Overview

The Ophthalmic Drugs Conference is returning for the 6th edition, taking place on the 20th-21st of November 2023, in London.

Register Today to get the Early Bird Rate Offer

What’s different this year?

Advances in ophthalmic medicine are needed as our population ages. In this course, we'll discuss ophthalmic drug delivery, cell and gene therapies, and conditions such as diabetic retinopathy, age-related macular degeneration, and glaucoma and help you shape the future of ophthalmology.

The only event that will:
The conference will be a variety of novel drugs and delivery techniques showing you promising clinical data. Other key areas will be gene therapy and artificial Intelligence with developments on the latest drug pipelines and clinical trials for you to expand your ophthalmic medicine portfolios. 

 

FEATURED SPEAKERS

Aniz Girach

Aniz Girach

Chief Medical Officer, ProQR Therapeutics
Daniel Chung

Daniel Chung

Chief Medical Officer, Sparing Vision
David  Tanzer

David Tanzer

Chief Medical Officer, OcuTerra Therapeutics
Kerrie Brady

Kerrie Brady

CEO, OcuTerra Therapeutics
LOIC LHUILLIER

LOIC LHUILLIER

COO, Exonate
Mark  Singh

Mark Singh

Non-Clinical Manager, Cell and Gene Therapy Catapult
Prabhu Velusami

Prabhu Velusami

Senior Director, Johnson & johnson
Richard Reschen

Richard Reschen

Director, Business Development & Licencing, MSD

Aniz Girach

Chief Medical Officer, ProQR Therapeutics
Aniz Girach

Aniz Girach, qualified as an Ophthalmologist (specialty in Retina), and worked in Cambridge (UK).
After having spent 11 years in the Clinical Practice/Academia, he joined the pharmaceutical industry with
Eli Lilly, focusing on retinal diseases. He has in total 24 years industry experience in roles with Merck (as
their Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development;
and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing
the development and approval of Ocriplasmin (Jetrea)—a first in class biologic therapy for retinal disease.
In total, he has led Teams to achieve 4 drug approvals in Ophthalmology. In his role as Chief Medical
Officer at Nightstar Therapeutics, he led and oversaw the development of their gene therapy programmes
for inherited retinal diseases, prior to their acquisition by Biogen. In addition to being an Honorary
Professor at Wills Eye Hospital, Philadelphia, USA, he is currently the Chief Medical Officer at ProQR
Therapeutics, leading the development of RNA therapies for genetic eye diseases. He is a member of 3
Scientific Advisory Boards for international ophthalmic organizations currently, and a reviewer for 5
peer-reviewed journals, including Eye and IOVS. He has been Chief Editor of 4 books and published over
70 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at
national/international ophthalmology meetings. He currently holds Independent Board of Directorship
positions for 2 Biotech companies.
His special interests are Medical Retina, and Genetic Therapy for Rare diseases.

Bernhard Maag

Head of Business Development, Vista Group (Switzerland), Veonet
Bernhard Maag

Daniel Chung

Chief Medical Officer, Sparing Vision
Daniel Chung

Dr. Chung is the Chief Medical Officer for SparingVision, an ocular genomic medicine company, focusing on gene agnostic gene therapy and CRISPR gene editing approaches to combat blinding diseases. Prior to his recruitment to SparingVision, Dr. Chung was the Ophthalmology Therapeutic Leader for Spark Therapeutics, Where he led the medical affair group and contributed to many other areas ranging from clinical development to commercial and business development. Dr. Chung was intimately involved with the development of Luxturna, the first gene therapy approved by the FDA and EMA for use in a blinding genetic disease. Prior to joining Spark Therapeutics, at the Scheie Eye Institute, University of Pennsylvania, working in research for retinal gene therapy.

David Tanzer

Chief Medical Officer, OcuTerra Therapeutics
David  Tanzer

David J. Tanzer, MD is board certified, fellowship trained ophthalmologist from the United States and is the Chief Medical Officer and Executive Vice President – Clinical and Medical Affairs with OcuTerra Therapeutics, a clinical stage biotech company headquartered in Boston, Massachusetts.
With over 25 years of clinical, research, development, launch, and executive leadership experience in the ophthalmology space, serving with the US Navy, Abbott Medical Optics, Johnson & Johnson Vision, and Novartis Pharmaceuticals, Dr. Tanzer is focused on bringing transformational change to therapeutic offerings for patients suffering from retinal vascular diseases by developing OTT166, a safe and effective topical treatment.
 

Kerrie Brady

CEO, OcuTerra Therapeutics
Kerrie Brady

Kerrie Brady is CEO and President (Designee) of OcuTerra Therapeutics Inc., a clinical stage ophthalmology company developing a novel eye drop, OTT166, designed to treat diabetic retinal disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic retinal disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity.
Prior to joining OcuTerra Kerrie was co-founder, Chief Business Officer and Executive Vice President, Corporate Strategy at Centrexion Therapeutics. She is an experienced international biopharmaceutical leader with a successful 30-year track record. Her focus has been founding entrepreneurial ventures and working with biopharma companies and research organizations on value creation for new and emerging technologies using her broad, cross-discipline, expertise in business, science and product development. Prior to founding Centrexion, Kerrie was co-founder and Chief Operations Officer for Vallinex Inc., Co-founder and Chief Operations Officer for Arcion Therapeutics Inc., and Founder and Chief Executive Officer of Traxion Therapeutics, Inc.
Leading up to her entrepreneurial career Kerrie worked in both public and private biotechnology companies in business development and operations roles leveraging her experience in product management and regulatory affairs obtained working for major pharmaceutical companies. Kerrie holds a Bachelor of Pharmacy from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in Biopharmaceuticals from the University of New South Wales.
 

LOIC LHUILLIER

COO, Exonate
LOIC LHUILLIER

Loic joined Exonate as Programme Director in 2016 and became Chief Operating Officer in 2019. He has an MSc in Neuroscience from Pierre and Marie Curie University, and a PhD in Cellular and Molecular Biology from the University of Houston. Loic held postdoctoral roles at INSERM (Paris) and Novartis (Basel), before becoming team leader at Lectus Therapeutics (Cambridge). He has spent the last 10 years leading preclinical and clinical projects as a consultant, translational research portfolio manager for the Biomedical Research Centre at King’s College London, and programme manager at Innovate UK.

Mark Singh

Non-Clinical Manager, Cell and Gene Therapy Catapult
Mark  Singh

Prabhu Velusami

Senior Director, Johnson & johnson
Prabhu Velusami

Prabhu Velusami is a Senior Director of Early Innovation Partnering for Datascience and Retina at Johnson & Johnson Innovation. He leads the identification and sourcing of early stage transformative innovation, and the subsequent shaping and execution of transaction opportunities across Johnson & Johnson’s datascience and ophthalmology businesses in EMEA.

He was previously a practicing ophthalmologist and was an Associate Director at the Boston Consulting Group in the lifesciences practice.
 

Richard Reschen

Director, Business Development & Licencing, MSD
Richard Reschen

Richard is Director, Business Development & Licensing in the global BD&L group of MSD (known as Merck & Co in the US and Canada). Within the team Richard is the Neuroscience and Ophthalmology Search & Evaluation lead for Europe/Middle East. During his 3.5 years at MSD Richard has co-led transactions with Curve Therapeutics and Proxygen. Prior to MSD, Richard spent 8 years at Oxford University Innovation in a series of roles, most recently as Principal Licensing & Ventures Manager. Richard has a business focused Master’s and PhD in Molecular Biology from the University of Cambridge.

Ruth Lloyd-Williams

Benefit Risk Evaluation Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
Ruth Lloyd-Williams

Viral Kansara

Vice President of Preclinical Development, Clearside Biomedical
Viral Kansara

Wen Lee

CEO, Action Against AMD
Wen Lee

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

David Tanzer, Chief Medical Officer, OcuTerra Therapeutics

clock

9:10

Lessons in regulatory guidance for ophthalmic medical devices

Ruth Lloyd-Williams

Ruth Lloyd-Williams, Benefit Risk Evaluation Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)

  • Risk management and ISO 14971
  • A look at some important international standards for ophthalmic products
  • Guidance on best practices for clinical investigation applications
  • clock

    9:50

    Omlonti: the novel EP2-receptor agonist for glaucoma / OHT treatment

    clock

    10:30

    Morning Coffee

    clock

    11:00

    PANEL DISCUSSION: Reviewing the evolving landscape of ophthalmic drugs R&D

  • An industry outlook into recent industry advances in ophthalmic drugs
  • Potential for novel partnerships or business models to advance R&D in ophthalmics
  • Thoughts on next generation approaches to improve ophthalmic drug discovery and development
  • Richard Reschen, Director, Business Development & Licencing, MSD

    Kerrie Brady, CEO, OcuTerra Therapeutics

    Prabhu Velusami, Senior Director, Johnson & johnson

    clock

    11:40

    Overview of regulatory landscape for ophthalmic drug developments

  • Overview of current regulatory framework relating to ophthalmic medicines.
  • Updates on recent ophthalmic drug approvals and latest guidances. 
  • Introduction to devices and combination approaches for novel ocular therapeutics. 

     

  • clock

    12:00

    Networking Lunch

    clock

    13:00

    Recent Developments in Suprachoroidal Microneedle-based Drug and Gene Delivery

    Viral Kansara

    Viral Kansara, Vice President of Preclinical Development, Clearside Biomedical

  • Suprachoroidal injection as a promising route of delivery for chorioretinal diseases
  • SCS Microinjector platform: Safety, Durability and Compartmentalized delivery
  • Preclinical and clinical proof of concept for SCS gene therapy and small molecule suspensions
  • clock

    13:40

    New Technologies in Diabetic Retinopathy Management

    David Tanzer, Chief Medical Officer, OcuTerra Therapeutics

  • Redefining Diabetic Retinopathy – from standard 7-field color fundus photos to non-invasive 3D assessment of peripheral vasculature
  • Screening and Diagnostics – earlier detection means improved treatment options; structure vs. function
  • Treatment – from old gold standard IVT to non-invasive options, allowing for acceptable earlier intervention
  • clock

    14:20

    Afternoon Tea

    clock

    14:50

    Regulatory approval is not the last hurdle

    Bernhard Maag

    Bernhard Maag, Head of Business Development, Vista Group (Switzerland), Veonet

  • Enhancing trial design through defined trial end point
  • A review of biomarkers as an eff ective drug target in clinical trials
  • Improving patient centricity via increased visual fi eld trial end points
  • clock

    15:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    David Tanzer, Chief Medical Officer, OcuTerra Therapeutics

    clock

    9:10

    Gene Therapy Considerations for Dry AMD

    Prabhu Velusami, Senior Director, Johnson & johnson

  • Overview  of pathogenesis of dry AMD
  • Therapeutic approaches being investigated for dry AMD
  • Gene therapies for GA - some considerations
     
  • clock

    9:50

    Non-Viral Gene Therapy Method for the sustained production of therapeutic proteins

    Francine Behar-Cohen

    Francine Behar-Cohen, Chief Innovation Officer, Eyevensys

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Transforming the treatment landscape for AMD and DMO with novel technologies

    LOIC LHUILLIER, COO, Exonate

  • Exploring modulation of alternative splicing as a new treatment modality
  • Expanding on VEGF as a therapeutic target through VEGF isoforms
  • Lessons learned from preclinical discovery and shaping the clinical development strategy
  • Overview of the in-patient Phase I trial
  • clock

    11:40

    A first-in-human trial of rod-derived cone viability factor (RdCVF) gene therapy in subjects with rod-cone dystrophy, a gene independent approach

    Daniel Chung, Chief Medical Officer, Sparing Vision

  • Expanding on the clinical development of novel gene therapies including SPVN06
  • The benefi ts of designing gene therapies to act independently of the causative gene mutation
  • An introduction to new clinical trials and future workings
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Non-clinical safety strategies for AAV-delivered gene therapies

    Mark  Singh

    Mark Singh, Non-Clinical Manager, Cell and Gene Therapy Catapult

  • A brief introduction to ATMPs, and of the use of the risk-based approach.
  • Discussion of the various non-clinical considerations of a fictional AAV gene therapy.
  • Discussion of the various biological aspects to be considered when developing a non-clinical strategy for AAV gene therapies.
  • clock

    14:00

    Applications of AI for Ocular Drug Discovey

  • The search for eff ective non-steroidal anti-infl amatory agents for non-infectious inflammation
  • JAK inhibition as an ocular anti-infl ammatory mechanism
  • Pre-clinical results of selective JAK inhibitors in animal models of ocular inflammation
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Enhancing understanding of ophthalmic disease progression through key imaging techniques

    Wen Lee

    Wen Lee, CEO, Action Against AMD

  • An introduction to retinal imaging and optic nerve disorders
  • Understanding non-human primates as an efficient model for imaging technologies
  • A review of recent advances in imaging technologies and next steps in overcoming key challenges
  • clock

    15:50

    Chairman’s Closing Remarks and Close of Day Two


    Chief Medical Officer
    ProQR Therapeutics
    Head of Business Development
    Vista Group (Switzerland), Veonet
    Chief Medical Officer
    Sparing Vision
    Chief Medical Officer
    OcuTerra Therapeutics
    CEO
    OcuTerra Therapeutics
    COO
    Exonate
    Non-Clinical Manager
    Cell and Gene Therapy Catapult
    Senior Director
    Johnson & johnson
    Director, Business Development & Licencing
    MSD
    Benefit Risk Evaluation Assessor
    Medicines & Healthcare Products Regulatory Agency (MHRA)
    Vice President of Preclinical Development
    Clearside Biomedical
    CEO
    Action Against AMD

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Past Speaker Presentation - Petra Kozma

    Download

    Brochure

    Download

    Past Speaker Presentation - Mitchell De Long

    Download

    Past Speaker Presentation - Kate Binley

    Download

    Past Speaker Presentation - Marion Munk

    Download

    Speaker Interview - David Tanzer

    Download

    Speaker Interview- Mark Singh

    Download

    Speaker Interview - Daniel Chung

    Download

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out